The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Integer Holdings expects its organic sales growth to improve in 2027, but that is a company forecast—not evidence that medtech as a whole will rebound after “one more weak quarter.” In April 2026, Integer reported modest first-quarter sales growth, lower adjusted earnings and a reduced full-year outlook. Other medical-device and healthcare-technology companies cited here reported growth or raised guidance, so the evidence points to uneven performance rather than a sector-wide downturn.
What Integer’s 2027 forecast actually says
Integer is a contract development and manufacturing organization (CDMO): it develops and manufactures medical-device components and products for customers, serving markets including cardio and vascular, neuromodulation, and cardiac rhythm management. Its results are therefore not a direct measure of every medical-device maker, much less the entire medtech industry.
In its April 2026 outlook, Integer said it expected to return to organic sales growth 200 basis points above the market in 2027. The statement is a forward-looking expectation from Integer management, not a reported result, an industry consensus or a guarantee. Integer’s forward-looking-statement caution says predictions are subject to risks, assumptions and uncertainties.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
The phrase “one more weak quarter” is not established by the cited company releases as a consensus forecast, and those releases do not identify which next quarter it means. It should not be read as a verified sector-wide prediction.
#1 Best Overall
Why Integer’s near-term outlook is subdued
First-quarter growth was modest, and adjusted earnings fell
Integer reported Q1 2026 sales of $439.6 million, up 0.5% year over year. Its organic sales growth was 1.3%, while adjusted EPS declined 8.4%. The company defines organic sales change by removing foreign-currency effects, acquisition contributions and the strategic exit of its Portable Medical business, so the organic figure is not interchangeable with reported growth or other companies’ measures.
The full-year forecast implied a reported sales decline
In April 2026, Integer forecast FY2026 sales of $1.805 billion to $1.835 billion, corresponding to a reported year-over-year decline of 3% to 1%. The company’s CEO, Payman Khales, said: “Given recent customer forecast updates and market dynamics, we believe it was prudent to further risk adjust our outlook.”
Rank #2
- Comes with secure packaging
- Easy to read text
- It can be a gift option
This forecast is the clearest basis for describing Integer’s outlook as weak. It does not establish that the whole industry—or even every market Integer serves—will have another weak quarter.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problemsOther company results show a mixed picture
The companies below reported different periods and use different measures. Treat them as examples of dispersion, not as a combined medtech growth rate or a sector index. “Reported,” “organic,” “constant currency,” and “core revenue” are not equivalent measures.
| Company and period | Reported result or outlook | How to read it |
|---|---|---|
| Integer, Q1 2026 | Sales of $439.6 million; growth of 0.5% reported and 1.3% organic; adjusted EPS down 8.4% | Integer’s organic measure excludes currency, acquisitions and the Portable Medical exit. |
| Integer, FY2026 outlook | Sales of $1.805 billion–$1.835 billion; reported change of −3% to −1% | Company forecast issued in April 2026. |
| Integer, 2027 outlook | Return to 200 basis points above-market organic sales growth | Forward-looking company expectation, not an industry forecast or realized result. |
| Baxter, Q2 2026 | Sales growth of 5% reported and organically; FY organic sales growth outlook raised to 2%–3% | Continuing-operations results exclude the former Kidney Care business. Baxter’s CEO said results benefited in part from a tariff refund not previously contemplated in guidance. |
| Zimmer Biomet, Q2 2026 | Net sales of $2.177 billion; growth of 4.8% reported and 4.0% organic constant currency | The company raised its full-year guidance. |
| Danaher, Q3 and FY2026 outlook | Non-GAAP core revenue growth forecast at 2%–3% year over year for Q3 and 3%–4% for FY2026 | Company forecasts; core revenue is a non-GAAP measure. |
| MiniMed, fiscal Q1 2027 | Sales of $843 million; growth of 17% reported and 16% organic | The company raised its fiscal 2027 organic revenue growth guidance. |
| AngioDynamics, fiscal Q1 2027 | Med Tech net sales growth of 13.2%; FY2027 Med Tech growth guidance reiterated at 12%–15% | Gross-margin guidance reflected a lower second-half expectation. |
| Edwards Lifesciences, Q2 2026 | Sales of $1.74 billion; growth of 13.6%; FY2026 constant-currency growth outlook raised to 10%–11% | Company-specific results and guidance. |
| BD, fiscal Q2 2026 | Revenue of $4.7 billion; growth of 5.2% reported and 2.6% foreign-exchange neutral | BD reaffirmed revenue guidance and raised adjusted EPS guidance. |
What the comparisons do—and do not—show
Baxter, Zimmer Biomet, MiniMed, AngioDynamics, Edwards Lifesciences and BD reported positive growth in the cited periods or raised or reaffirmed guidance. Danaher projected low-single-digit core revenue growth for 2026. Integer’s lowered outlook sits within that varied set of company-specific results; it does not define it.
- Quarterly results are not full-year forecasts. A company can post growth in one quarter while expecting a different pace for the year.
- Growth bases differ. Reported sales can reflect currency and portfolio changes; organic, constant-currency and non-GAAP core measures adjust results in different ways.
- Sales and earnings can move differently. Integer’s modest sales growth accompanied an adjusted EPS decline, so revenue alone does not capture its quarter.
- Fiscal calendars and business mixes vary. These companies span different products and markets, and their cited reporting periods are not all the same.
How to interpret the 2027 rebound claim
The most defensible reading is narrow: Integer expects its organic growth to recover to a level 200 basis points above the market in 2027, following a risk-adjusted 2026 outlook. That forecast depends on future market conditions, customer demand and other assumptions; it is not proof that a rebound will occur.
Rank #4
For readers assessing the broader sector, the cited releases support a mixed outlook, not the claim that all of medtech must endure one more weak quarter before improving. Any stronger claim would require an attributable forecast defining both the relevant companies and the quarter in question.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
